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osting by EAbstract This study was carried out to evaluate the anti-obesity effect of Vernonia amygdalinaDel.
(VA) supplemented diet. VA leaf powder was fed at 5% and 15% to diet-induced obese rats for
4 weeks and its effect compared with orlistat (5.14 mg/kg p.o.), an anti-obesity drug. Food intake,
body and organ weights, total body fat, some lipid components and amino transaminase activities
in serum, hepatocytes and brain; as well as serum glucose, were measured during or at end of the
study. Result showed respective decrease of 12.78% and 38.51% in body weight gain, of VA fed rats
against 17.45% of orlistat at end of study (P< 0.05); but with no effect on food intake. Total body
fat was lowered by 28.04% and 30.02% vs. obese control rats (CDC) (P< 0.05). Furthermore,
serum triacylglycerol (TG), serum and brain total cholesterol (TCHOL), were down regulated at
15% VA supplementation (P< 0.05). Serum glucose which increased in obese rats by 46.26%
(P< 0.05) vs. NC, indicating intolerance, was restored by VA (38.75% and 34.65%) and orlistat
(31.80%) vs. CDC (P< 0.05). VA diet also exerted hepato-protection, via lowering serum alaninent of Biochemistry, College of
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386 I.J. Atangwho et al.amino transaminase (ALT) (41.35% and 27.13%) and aspartate amino transaminase (AST)
(17.09% and 43.21%) activities (P< 0.05). Orlistat had no effect on these enzymes. Histology of
adipose tissue corroborated the changes on total body fat. We concluded that, diet supplemented
with VA can attenuate dietary obesity as well as ameliorates the potential risks of hepato-toxicity
and glucose intolerance associated with obesity.
ª 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Obesity is fast becoming a medical condition of global con-
cern, particularly due to its consistent association with in-
creased prevalence of cardiovascular diseases, diabetes
mellitus, hypertension and some forms of cancers (Xia et al.,
2010). It is now certain that genetic predisposition and con-
sumption of high energy foods are the commonest pathoge-
netic factors (Thompson et al., 2011). Weight reduction, via
dietary modulation is therefore the target of choice of many
therapeutic measures. Subramine and orlistat the approved
conventional drugs, promote about 5–10% loss of weight,
and best, only when used in conjunction with diet, exercise,
and behavior change regimens (Kumar et al., 2011). This is
grossly inadequate and unsatisfactory given the present size
of the market and current status for development of these
drugs (Shrestha et al., 2007). The reported minor and grave
side effects of the drugs, as well as weight rebounds when dis-
continued (Ellrichmann et al., 2008), have necessitated a new
dimensional approach into the search for anti-obesity medi-
cines. Incidentally, numerous preclinical and clinical studies,
with various herbal medicines have reported signiﬁcant
improvement in controlling body weight, without any notice-
able adverse effects (Kumar et al., 2011).
Vernonia amygdalina Del. (VA) is a nutritionally and
pharmacologically responsive vegetable, commonly called
‘‘African bitter leaf’’ used in West Africa particularly, Nigeria
in the preparation of the popular ‘‘bitter leaf soap’’ served at
homes and restaurants. Its nutritional and medicinal uses and
scientiﬁc studies have respectively been articulated in two exten-
sive reviews by Ijeh and Ejike (2010) and Farombi and Owoeye
(2011). A number of earlier studies with extracts from the plant
(Ekpo et al., 2007; Ezekwe and Obidia, 2001) and the leaves
incorporated into diet by weight (Ugwu et al., 2009, 2011) have
documented the lipid modulating effect in normal adult rats. In
Pharmacologically induced hyperlipidemic models, Adaramoye
et al. (2008) have shown the anti-hyperlipidemic activity of ex-
tracts from the plant extract.
However, these studies are neither in-depth nor modeled
the practical societal problem of obesity, using diet induced
obese models, combined with a dietary approach to interven-
tion. The present study is therefore conducted to investigate
the possible anti-obesity effect of VA leaves incorporated by
weight in diet of diet-induced obese rat models.2. Materials and methods
2.1. Experimental diets
Cafeteria diet (CD), the fattening diet, was formulated accord-
ing to the method of Kumar et al. (2011) with some modiﬁca-tions. The CD is comprised of three sets of diets A, B, and C
formulated as below:
A ¼ condensed milk ð24 gÞ þ whole grain bread ð24 gÞ
þ rat pellet ð52 gÞ  48% replaced:
B ¼ chocolate ð9 gÞ þ biscuits ð8 gÞ þ dried coconut ð18 gÞ
þ rat pellet ð55 gÞ  45% replaced:
C ¼ cheese ð24 gÞ þ boiled potato ð30 gÞ þ rat pellet ð46 gÞ
 54% replaced:
Each of diets A, B and C was then supplemented with VA
at 5% or 15% by weight and fed in succession to the animals.
2.2. Plant material and standard drug
VA leaves were obtained from the Endocrine Research
Farm, University of Calabar and authenticated in the
Department of Botany, of the same institution. The leaves
were air-dried (25–29 C) and thereafter milled into coarse
powder and stored in air-tight plastic containers, from where
portions were weighed out for supplemented CD formula-
tion. Fresh leaf samples were prepared every week until
end of study. Orlistat (Xenical Pharmaceuticals, Japan) ob-
tained from Karmel Pharmacy, 112 Goldie Street, Calabar,
Nigeria, was reconstituted in distilled water and adminis-
tered orally as 5.14 mg/kg body weight, a dose simulated
from the human regimen.
2.3. Animals
Thirty Wistar rats (51–58 g) obtained from the Animal Re-
source, Department of Zoology and Environmental Biology,
University of Calabar, were used for this study. The rats were
allowed to acclimatize in the animal house of department of
Biochemistry, where the experiment was conducted under con-
trolled temperature (25–29 C). The animals were allowed free
access to food and water, and 12 h light/dark cycle. The proto-
col was in line with the guidelines of the National Institute of
Health publication (1985) for Laboratory Animals Care and
Use, and was approved by the College of Medical Sciences’
Animal Ethics Committee, University of Calabar.
2.4. Experimental protocol
The rats were divided into ﬁve groups of 6 rats each. The
average body weights of rats in the ﬁve groups were similar
at onset of the experiment. Group 1, the normal control
(NC), was fed rat pellet only, throughout the 10 weeks of
study. Group 2, cafeteria-diet-fed control (CDC), was also
fed CD only for the 10 weeks of study, whereas groups 3–
5, STDC, VAS 1 and VAS 2 were, fed CD only for the ﬁrst
6 weeks of the study and thereafter in the last 4 weeks, CD
Figure 1.1 Body weight gain after 6-week cafeteria diet feeding
(BWG1) and body weight gain to total diet ratio (G1/TD1) within
the period. Values are the mean ± SD (n= 6); NC, normal pellet;
CD 1–4 cafeteria diet only.
Figure 1.2 Body weight gain after 4-week intervention with VA
supplemented diet or orlistat (BWG 2) and body weight gain to
total diet ratio (G2/TD2) within this period. Values are the
mean ± SD (n= 6). NC, normal pellet; CDC, cafeteria diet only;
STDC, orlistat treated; VAS 1, 5% VA and VAS 2, 15% VA,
aP< 0.05 vs. NC, bP< 0.05 vs. CDC.
Figure 1.3 Total diet (TD) consumed before 6 weeks (6WK) and
after 4 weeks (4WK) VA supplemented feeding.
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CD and 15% VA supplemented CD, respectively. The three
CDs A, B, C alone or supplemented were presented to the
animals on days 1, 2 and 3 and then repeated in succession
until the end of study. Fresh diet for each group was com-
pounded every day, to avoid spoilage, particularly the milk
products. The food intake was recorded by measuring the
difference between the pre-weighed diet presented to the rats
and the weight of 24 h leftover. Food spillage was also re-
corded and adjusted for, in calculating the food intake.
Body weight was measured two to three times per week,
but consistently. Six weeks and 10 weeks body weight gains
were calculated as difference in animal body weight on
weeks 6 or 10 and weight at onset of experiment, whereas
cumulative weight gain was calculated as body weight on
the day of measurement minus the body weight recorded
at onset of the experiment (daymeasurementday0) (Zhou
et al., 2011).
2.5. Body fat and organ weight measurements
At end of the experiment, the rats were euthanized and whole
blood were collected by cardiac puncture, whole brain, liver
and the kidneys were surgically removed, and wet weights were
measured with an analytical balance after blotting. Total body
fat (perirenal and epididymal fat pads) was removed and wet
weights were recorded. Percentage/relative total body fat was
calculated thus: w/W · 100% where, w is the wet weight of
the fat pad and W, the ﬁnal body weight of the animal before
it was killed. Relative organ weights were similarly calculated.
The tissues were immediately divided into two portions each.
One part stored frozen preparatory to biochemical assays
and the other part and fat pad ﬁxed in buffered 10% formalin
preparatory to histological analysis.
2.6. Biochemical analyses
Serum glucose, triacylglycerol (TG), total cholesterol
(TCHOL) and high density lipoprotein cholesterol (HDL-C),
as well as alanine amino transaminase (ALT) and aspartate
amino transaminase (AST) activities were determined with
analytical kits from Randox Laboratories Ltd. (Admore Dia-
mond Road, Crumlin, Co., Antrim, United Kingdom). TG,
TCHOL, HDL-C, and ALT and AST activities were also
determined in homogenates prepared from liver and brain tis-
sues. In brief, 1 g of each tissue was homogenized in 5 ml of
phosphate buffer (pH 7.4), centrifuged at 4000 rpm for
15 min and the supernatant was used for the assays.
2.7. Histopathological studies
Fixed adipose tissues were sectioned with microtome (5 lm
thickness), ﬁxed in slides and stained using Harry’s Haematox-
ilin and Eosin staining procedures. The slides were viewed un-
der light microscope and photomicrographs were taken (400·).
2.8. Statistical analysis
Data were expressed as the mean ± SD. ANOVA was used for
analysis, followed by least square difference (LSD) post hoc,
using SPSS software version 15.0. Difference was considered
signiﬁcant at P< 0.05.3. Results
3.1. Effect of VA supplemented diet/orlistat on body weight and
food intake
Although body weights were similar at onset of the experiment
(54.82 ± 3.25 g), 6-week initial feeding of cafeteria diet (CD)
Figure 1.4 Cummulative body weight gain of rats fed cafeteria diet alone and with VA supplemented diet or orlistat. Data represent the
mean ± SD (n= 4–6 per group); *P< 0.05 vs. CDC.
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45% over the NC (Fig. 1.1). But 4-week intervention with
VA supplemented diet at 5% and 15% dose-dependently de-
creased body weight gain (12.78% and 38.51%), compared
to CDC. Oral orlistat also decreased body weight gain by
17.45%, relative to CDC, at end of the study (Fig. 1.2). How-
ever, there was no signiﬁcant difference among groups in food
consumption before and after intervention, implying that
neither VA nor orlistat, adversely affected dietary intake
(Fig. 1.3). Cumulative body weight gain calculated over the
10 weeks, showed a sequential increase which was not signiﬁ-
cantly different among groups, until 10 days after the com-
mencement of VA supplemented feeding. The gain was
increasingly lower and lower in the VA diet fed rats compared
to the CDCs (P< 0.05) until end of the study, in a dose-
dependent manner (Fig. 1.4).
3.2. Effect of VA supplemented diet/orlistat on % body fat and
organs weights
The percentage body fat at end of the study was lower in ani-
mals fed 5% and 15% VA diet than in the CDCs by 28.04%
and 30.02% respectively (P< 0.05). Body fat of orlistat-treated
rats was intermediate, and did not differ signiﬁcantly fromFigure 2 Body fat measured at end of study by dissection.
%TWAT, total white adipose tissue/body weight; %PWAT,
perirenal white adipose tissue/body weight; %EWAT, epididymal
white adipose tissue/body weight. Data represent the mean ± SD
(n= 4–6); aP< 0.05 vs. NC.either CD fed control or VA supplemented groups (Fig. 2).
Weights of liver, kidneys and brain were lower in CDC com-
pared to NC (P< 0.05). However, orlistat or VA diet restored
brain weight (P< 0.05), but slightly increased the liver and
kidney weights (Fig. 3).
3.3. Effect of VA supplemented diet/orlistat on serum glucose
Serum glucose was higher (46.26%) in CDC than NC
(P< 0.05), indicating glucose intolerance. However, 4-week
oral orlistat, or dietary feeding with 5% and 15% VA diet de-
creased the glucose respectively by 31.80%, 38.75% and
34.65% (P< 0.05), to levels similar to the NCs (Fig. 4).
3.4. Effect of VA supplemented diet/orlistat on lipid components
3.4.1. Serum
Serum TG was higher in CDC than NC rats fed pellets only
(P< 0.05). However in the VA supplemented groups, the
TG was lower than the CDC (P< 0.05) (Fig. 5.1). Serum
TCHOL was down regulated by VA supplemented feeding at
15% (P< 0.05) relative to CD. HDL-C was however not sig-
niﬁcantly impacted by the treatments.Figure 3 Organ weights to body weight ratio at end of study
(10 weeks). Values are the mean ± SD (n= 4–6). KWT, kidney
weight; BWT, brain weight; LWT, liver weight; aP< 0.05 vs. NC,
bP< 0.05 vs. CDC.
Figure 4 Effect of VA supplemented diet/orlistat on serum
glucose concentration at end of study. Values are the mean ± SD
(n= 6); aP< 0.05 vs. NC; bP< 0.05 vs. CDC. Figure 5.1 Effect of VA supplemented diet/orlistat on selected
serum lipid components. Values are the mean ± SD (n= 4–6).
HDL-C, high density lipoprotein cholesterol; TCHOL, total
cholesterol; TG, triacylglycerol; aP< 0.05 vs. NC; bP< 0.05 vs.
CDC.
Figure 5.2 Effect of VA supplemented diet/orlistat on lipid
components measured in brain tissue. Values are the mean ± SD
(n= 4–6). HDL-C, high density lipoprotein cholesterol; TCHOL,
total cholesterol; TG, triacylglycerol; aP< 0.05 vs. NC; bP< 0.05
vs. CDC.
Figure 5.3 Effect of VA supplemented diet/orlistat on lipid
components measured in liver tissue. Values are the mean ± SD
(n= 4–6). HDL-C, high density lipoprotein cholesterol; TCHOL,
total cholesterol; TG, triacylglycerol; aP< 0.05 vs. NC; bP< 0.05
vs. CDC.
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There was signiﬁcant increase in brain TCHOL (P< 0.05) of
CDC compared to NC. A 4-week intervention with oral
orlistat and 15% VA diet caused a decrease in the levels
(P< 0.05) (Fig. 5.2). Brain TG and HDL-C were not signiﬁ-
cantly impacted by intervention.
3.4.3. Liver tissue
Hepatic TCHOL was increased (P< 0.05) in CDC compared
to NC. Intervention with orlistat or VA diet decreased the cho-
lesterol concentration relative to CDC (Fig. 5.3). However,
this decrease was only signiﬁcant in orlistat treated group
(P< 0.05). Hepatic TG was also modulated by VA diet while
HDL-C was not signiﬁcantly impacted.
3.5. Effect of VA supplemented diet/orlistat on ALT and AST
activities
3.5.1. Serum
Compared with the CDC, 5% and 15% VA diets respectively
lowered serum ALT (41.35% and 27.13%) and AST (17.09%
and 43.21%) activities (Fig. 6.1). Oral orlistat was found to
raise ALT activity over CDC by 15.29%.
3.5.2. Liver tissue
The observed change in hepatic ALT activity was the opposite
of that in serum. Four-week feeding of VA diets at 5% and
15% respectively increased ALT activity by 47.52% and
22.95% (P< 0.05). Oral orlistat also had no effect on hepatic
ALT activity. Hepatic AST activity was not signiﬁcantly chan-
ged at end of the study (Fig. 6.2).
3.6. Effect of VA supplemented diet/orlistat on adipose tissue
histology
Photomicrographs of the histology of white adipose tissue of
the control and treated rats at the end of the study are
shown in Fig. 7 (Plates 1–5). The histology of WAT showed
numerous adipocytes tightly packed and clumped together in
the obese rats (Plate 2), compared to the NCs which showed
normal adipocytes distribution and cells of regular sizes
(Plate 1). However, 15% VA supplemented diet indicated
histology similar to the NCs, suggesting inhibition of the
hyperplasic growth of the adipocytes (Plate 5). The effectof orlistat and 5% VA supplemented diet were mild on
the histological architecture of the adipose tissue (Plates 3
and 4). These observations of the adipose tissue histology
correlate to % body weight results.
Figure 6.1 Effect of VA supplemented diet/orlistat on serum
amino transaminase activities. Values are the mean ± SD (n= 4–
6); SALT = serum alanine amino transaminase; SAST = serum
asparate amino transaminase; bP< 0.05 vs. CDC.
igure 6.2 Effect of VA supplemented diet/orlistat on liver
nzyme activities measured in liver tissue. values are the
ean ± SD (n= 4–6); LALT = liver alanine amino transami-
ase; LAST = liver aspartate amino transaminase; bP< 0.05 vs.
DC.
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The potential of VA leaves as medication for dietary obesity
was studied. Cafeteria diet, so-named by Kumar et al. (2011)
compounded with processed and fast foods up to 45–54% of
main course diet fed for 6 weeks, raised animals’ body weight
by 25–45% above rats fed pellets only. On the basis of this,
obesity model was successfully produced in conformity with
the deﬁnition of Pi-Sunyer (1991): weight >20% above opti-
mal, taking normal control rats as the optimum. Intervention
with VA supplemented diet down regulated the animals’ body
weights consistent with our earlier report (Atangwho et al.,
2007a) and other researchers (Igile et al., 1995), though these
earlier studies were carried out in normal animal subjects. De-
spite the characteristic bitter taste of VA leaves, food intake
was not affected. An earlier investigation with broilers had
also shown that feeding VA leaves as a substitute to maize-
based diet up to 300 g/kg did not affect food intake and efﬁ-
ciency (Aregheore et al., 1998). This null effect on food intake,
and the successive decrease in body weight gain, which became
statistically signiﬁcant only about 10 days after commence-
ment of supplemented feeding; and continued to the end of
experiment, strengthens the believe that weight reduction was
indeed a consequence of the ingested VA leaves.
Measurement of adipose tissue weight has been used as a
valid index in obesity related studies. For the ﬁrst time, the
present study showed a signiﬁcant reduction in total body fat
by feeding VA supplemented diet. WAT weight reduction ap-
pears as valid mechanism by which many anti-obesity medici-
nal plants exert their effects (Xia et al., 2010; Kumar et al.,
2011; Kim et al., 2011). Although, we do not understand for
now, how this WAT weight reduction is achieved; it is plausi-
ble that VA with reported hormone modulatory effect in dia-
betes, a metabolic condition akin to obesity, may also
inﬂuence the actions of the several adipose tissue hormones
such as the adiponectins. This is however, a subject for further
research. The intermediate action of orlistat on WAT weight
was expected, since orlistat exerts its action by sparing fat
absorption in the GIT, rather than direct effect on adipose tis-
sues (Ellrichmann et al., 2008). A longer period is required for
overt effect on adipose cells, which probably explains why
soon after withdrawal from clinical treatment with orlistat,
weight rebounds. In this light alone, VA may be preferred to
orlistat as a management for obesity.Glucose intolerance, the link between obesity and diabetes
(Kannel et al., 1979; Akiyama et al., 1996) was observed in
the CDCs (46.26% above normal threshold). This agrees with
Akiyama et al. (1996) who in their work, reported increased
blood glucose in mice made obese by feeding a high fat diet
for 28 days. VA supplemented feeding was shown for the ﬁrst
time to restore this intolerant condition. In related studies
chloroform and ethanol extracts of VA respectively lowered
serum glucose in normoglycemic and diabetic rats (Gyang
et al., 2004; Atangwho et al., 2007b). This implies that VA
may possess some prophylactic action against diabetes melli-
tus, in dietary feeding – a subject for further research.
Serum TG and TCHOL levels were decreased in VA fed
rats in agreement with a previous report (Adaramoye et al.,
2008). Although in the earlier report, VA extract was given
pharmacologically, it is clear that this can be reproduced using
dietary protocols, the most tolerable route of therapy. As in
our previous studies with diabetic subjects (Atangwho et al.,
2007a), serum HDL-C was not impacted by VA supplemented
feeding, probably requiring a longer period for redistribution
of the high protein component of the molecule. Hepatic lipid
proﬁle result paralleled that in serum. Cafeteria diet produced
fatty liver, evident in increased TG and TCHOL levels, similar
to the obesity model of Kumar et al. (2011). Four-weeks feed-
ing with VA supplemented diet, decreased lipids but to a lower
extent compared to orlistat. In the brain cells where TCHOL
was also high following the 6-week CD, 15% VA supple-
mented feeding produced attenuation effect on TCHOL simi-
lar to orlistat. V. amygdalina may therefore share some
mechanism with orlistat in its anti-obesity effect.
The activities of ALT and AST were signiﬁcantly raised in
CD fed rats, indicating a hepatotoxic tendency, imposed by
obesity. Kim et al. (2011) have also observed signiﬁcant in-
crease in serum ALT activity in animal model of obesity. Sup-
plemented feeding with VA but not orlistat, restored the
enzyme activities to levels even lower than normal control.
This may be an indication that VA has added advantage of
hepato-protection, when used to manage obesity. The hep-
ato-protective effect of VA extract in alloxan-induced diabetic
subjects was earlier reported in our laboratory (Atangwho
et al., 2007c). Decrease in hepatic ALT activity with CD feed-
ing, was also restored by supplemented VA feeding. The hepa-
tic fat deposition could have disrupted the cell integrity therebyF
e
m
n
C
Figure 7 Photomicrographs of white adipose tissue histology (400·) of rats at end of the study. Numerous deposits of adipocytes tightly
packed and clumped together of plate 2, indicate hyperplasic obesity in untreated obese rats, compared to the NCs with normal adipocytes
distribution and cells of regular sizes (Plate 1). Obese rats fed VA supplemented diet at 15% indicate histology similar to NC, suggesting
an inhibition of the hyperplasic growth of the adipocytes (Plate 5). The effect of orlistat and 5% supplemented feeding were mild on the
histological architecture of the adipose tissue (Plates 3 and 4).
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decrease in obese rats. It was only necessary that VA supple-
mented feeding which modulated the fatty liver, also reversed
the seeming damage by restoring the hepatic enzyme activity.
Numerous deposits of tightly packed and clumped adipo-
cytes were seen in obese WAT histology depicting as increase
in number of adipocytes – hyperplasia. Adipose tissue develop-
ment in young mice and rats is a combination of two phases in
which the ﬁrst involves stem cell differentiation and in the sec-
ond phase, the differentiated small cells gradually ﬁll up with
triacylglycerol (MacKellar et al., 2010). The animals in this
study may yet have been in the cell differentiation stage partic-
ularly that at onset of experiment, the animals were just about
3 weeks. Moreover, the entire duration of study was relatively
short. However VA supplementation at 15% indicated histol-
ogy similar to normal control, suggesting an inhibition of the
hyperplasic growth of the adipocytes. This opined adipocyte
growth inhibition by VA supplemented feeding may be similar
to its reported action on certain tumor cell, through which it has
found relevance in treatment of breast cancers (Izevbigie, 2003).5. Conclusion
VA fed as percentage dietary replacement can effectively atten-
uate obesity of dietary origin, via modulation of body and adi-
pose tissue weights, cellular architecture and lipid metabolism,
without affecting food intake. Additionally, the potential risks
of hepatotoxicity and intolerance in glucose are alongside ame-
liorated. Further research is however needed to elucidate detail
mechanism(s) by which this action is exerted.
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